Effect of Bevacizumab Combined with Standard Chemotherapy Regimen on Immune Function and Survival Situation of Patients with Advanced Ovarian Cancer
Objective:To observe the effect of Bevacizumab combined with standard chemotherapy regimen on immune function and survival situation of patients with advanced ovarian cancer.Method:A total of 76 patients with advanced ovarian cancer admitted to Ganzhou People's Hospital from February 2021 to December 2022 were randomly divided into two groups,with 38 cases in each group.The control group was treated with standard chemotherapy regimen(Paclitaxel Liposome+Carboplatin),on this basis,the observation group was treated with Bevacizumab.The clinical efficacy,immune function,tumor markers,adverse reactions and survival situation were compared between the two groups.Result:The total effective rate and 1-year survival rate in the observation group were higher than those of control group(P<0.05).After treatment,the levels of human epididymis protein 4(HE4),carbohydrate antigen 125(CA125)and CD8+in observation group were lower than those in control group,and CD3+and CD4+were higher than those in control group,the differences were statistically significant(P<0.05).There were no significant differences in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Bevacizumab combined with standard chemotherapy regimen can improve the clinical treatment effect of advanced ovarian cancer,reduce the levels of tumor markers,improve immune function,and promote the short-term survival rate of patients.
Ovarian cancerBevacizumabPaclitaxel LiposomeCarboplatinImmune function
万方数据
维普
